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Abstract
Objective: Missing forms may pose problems in health related quality of life (QOL) studies, because the
absence of a QOL measure may be related to the patient’s health and hence to the patient’s QOL itself.
Studying patterns of missingness, dropout, and the possible impact of missing data on QOL measures is an
important step in reporting outcomes of QOL studies. We study patterns of dropout and evaluate the
impact of missing forms in the TME QOL substudy. Methods: Patients with rectal cancer, randomized to
receive either radiotherapy plus total mesorectal excision (TME) or TME only were included in the TME
trial. QOL was evaluated in 1302 Dutch patients, before treatment, and 3, 6, 12, 18 and 24months after
surgery. Here only the visual analogue score (VAS) was studied. Results: At baseline, differences between
VAS scores were found with respect to whether the QOL forms were dated before or after radiotherapy and
surgery. Differences were small between different statistical methods accounting for dropout; only a cross-
sectional analysis gave biased results. Conclusion: The results of the sensitivity analysis indicated that a
linear mixed model analysis is a reliable and attractive approach for this study.
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Introduction
The occurrence of missing values is a virtually
unavoidable problem in clinical studies in general.
In health related quality of life studies in particu-
lar, missing values pose problems since the absence
of a value at a certain point in time may be related
to the severity of disease of the patient. Since this
severity of disease may determine the quality of life
score, absence or presence of the value is then
directly related to the unobserved outcome. For
the subsequent statistical analysis, data missing
not at random (MNAR) are a definite problem,
since summarizing the available data at any time
point will generally result in an overestimation of
the quality of life, the reason being that patients
with poor quality of life will have a higher prob-
ability of being missing. While missing data may
pose serious problems, there are of course other
reasons for data being missing that are perhaps
not related to illness. Patients may have forgotten
to return their questionnaires or may have re-
turned them too late; logistic problems may have
resulted in the questionnaires not having been
processed adequately, either before sending or
after receiving them [1]. This calls for the need to
incorporate patterns of missingness or dropout
into the statistical analysis. A first step towards
formulating a model explicitly modelling dropout
should be an assessment of how many missing
values occur at each of the scheduled time points
and why values are missing. Then, since many
methods incorporating dropout often make un-
testable assumptions, a sensitivity analysis com-
paring a number of such methods allow for better
evaluation of how conclusions depend on the
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missing data mechanism. We illustrate these steps
using data from a large randomized clinical trial in
rectal cancer treatment.
In rectal cancer, the quality of life is related to
the prognosis of the patient, but also to the impact
of the disease and treatment on patients health
status. Local recurrences are a major problem,
since they cause severe disabling symptoms and
are difficult to treat. Over the past decade, the
introduction of a new surgical technique, total
mesorectal excision (TME), has reduced the
number of local recurrences considerably [2, 3]. In
addition, short-term preoperative radiotherapy
has demonstrated to improve local control in
resectable rectal cancer [4]. In a large randomized
study the value of short-term preoperative radio-
therapy (55 Gy) was evaluated in patients with
resectable rectal cancer and operated with the
TME technique. Therapeutic outcomes have been
reported previously and demonstrated a significant
decrease in the local recurrence rate at 2 year:
8.2% in the TME alone group vs. 2.4% in the
radiotherapy and surgery group [5]. Quality of life
and cost outcomes were secondary endpoints in
the trial. Questionnaires on health related quality
of life were to be filled out and returned by the
patients before randomization (pre), and at 3, 6,
12, 18 and 24 months after surgery.
The purpose of this paper is twofold: first, to
give an assessment, as precise as possible, of how
much data is missing at each scheduled quality of
life measurement and for what reason. The second
purpose is to compare a number of analysis
strategies, some of them incorporating informative
dropout in the methods, in order to establish a
reliable and simple method of analysis.
Methods
Study design
From January 1996 until December 1999, 1861
patients were randomized to preoperative radio-
therapy with 55 Gy followed by standardized
TME surgery or to TME surgery only. In- and
exclusion criteria have been described in detail
elsewhere [5]. The majority of the included patients
(1530) were from the Netherlands; the other 331
patients were included by Swedish, other Euro-
pean and Canadian co-investigators. Quality of
Life was evaluated in Dutch patients only. In-
formed consent was obtained from all patients for
the study and was separately obtained for the
quality of life study. All patients underwent sur-
gery according to the Total Mesorectal Excision
principle, as advocated by Heald [2]. Patients as-
signed to preoperative radiotherapy received a
total dose of 25 Gy in 5 fractions over 5–7 days,
followed by TME within 10 days from start of
radiotherapy.
Quality of life assessment
Patients were requested to fill out a quality of life
questionnaire at the following time points: pre-
treatment, 3, 6, 12, 18 and 24 months after surgery.
Patients who failed to return two consecutive
questionnaires were considered as withdrawn from
the study and did not receive further question-
naires. The following time-windows were allowed:
3 months (1.5–4.5), 6 months (4.5–9), 12 months
(9–15), 18 months (15–21) and 24 months (21–27)
months. Forms with no date on it or outside the
time-windows were considered missing. The effect
of pretreatment forms filled in before or after
randomization, start of radiotherapy and surgery
was evaluated.
Health-related quality of life was assessed by the
patients using the Rotterdam Symptom Check List
(RSCL) [6], a questionnaire with 38 items which
contains a physical and a psychological distress
sub-scale. In addition to this, patients were re-
quested to score their general well-being over the
last week on a Visual Analogue Scale (VAS). The
patients were asked to rate their well-being by
placing a mark on a 100mm horizontal line, an-
chored by optimal health and death. The score is
the number of millimeters from the ‘death’ anchor
to the mark, divided by 100. For the purpose of
this paper, only VAS scores are used.
Statistical analysis
Assessment of missingness
VAS scores were compared according to whether
the quality of life forms were dated before, at, or
after day of randomization, start of radiotherapy
(RT+TME group only), and surgery, both for all
patients and for the treatment groups separately.
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One-way ANOVA with Bonferroni correction for
multiple testing was used for testing differences.
The independent samples t-test was used for test-
ing differences between treatment groups.
Because many patients were excluded from the
baseline measurement because the forms were fil-
led in and/or returned too late, we divided patients
with complete quality of life followup into three
categories. In the first one all forms are present
(note that a particular VAS score could still be
missing due to missing the VAS item or undeter-
minable score), the second category consists of
those patients of whom only the first quality of life
form is missing, the third consists of all other pa-
tients and is a heterogenous mix of patients that
have at least one form missing (excluding patients
with only baseline form missing). Differences be-
tween VAS scores were investigated between these
three groups using one-way ANOVA with Bon-
ferroni correction for multiple testing.
All analyses in this subsection were done with
SPSS 11.0 (Chicago).
Comparison of analysis strategies
Missing data are typically divided into three cate-
gories, according to the division made by Rubin
[7]: missing completely at random (MCAR),
missing at random (MAR) and missing not a
random (MNAR).
Let yi denote the vector of complete observa-
tions of patient i; denote the observed and missing
values of the patient by yobsi and y
miss
i respectively
and let ri be a vector of 0’s and 1’s indicating
whether or not the corresponding yi component is
missing or not.
The strictest assumption of MCAR specifies
that the probability of a missing observation is
independent both of observed and of missing
observations, i.e.
P ðrijymissi ; yobsi Þ ¼ PðriÞ:
The MAR assumption specifies that the proba-
bility of a missing observation may depend on the
observed, but not on the missing data,
P ðrijymissi ; yobsi Þ ¼ Pðrijyobsi Þ:
Finally, the MNAR assumption specifies that the
probability of a missing observation may depend
both on the observed and on the missing obser-
vations,
Pðrijymissi ; yobsi Þ ¼ P ðrijymissi ; yobsi Þ:
When covariates are incorporated into the analy-
sis, these assumptions need to be rephrased
slightly, see Rubin [7].
In this paper we concentrate on dropout.
Dropouts at a certain time point are defined as
patients who did not submit a valid form at that
specific time point or any later time point. For
data that are missing before dropout we assume
that they are MAR. Moreover, distinguishing be-
tween MAR and MNAR is intrinsically difficult
and often requires untestable assumptions [8].
We report three different analyses, each of
which will give unbiased results under different
assumptions on missingness.
The available cases or cross-sectional analysis
refers to a straight-forward analysis, where for each
point in time only those cases are considered with
non-missing data. This analysis gives unbiased re-
sults under MCAR. Differences between treatment
groups are tested at each time-point with a two-
sample t-test. p-values are presented without cor-
rection for testing at multiple time-points.
The mixed model [9] approach assumes random
patient effects and fixed effects of time (as cate-
gorical variable) and treatment (and interaction).
This implies that average VAS scores differ from
patient to patient, but mean changes over time are
identical for patients in the same treatment group.
The random patient effects induce (positive) cor-
relation between VAS scores of the same patient at
different time points. This method is also known as
repeated measures analysis of variance. Differences
between treatment groups are tested by defining
linear combinations of the estimated regression
coefficients in the model (contrasts) and testing
their significance using Wald’s test. A mixed model
will give unbiased results under MAR.
Pattern-mixture models [9–11] assume that data
are missing at random within a number of pre-
specified patterns p ¼ 1; . . . ; P ; in our situation a
pattern corresponds to a dropout time. Patients
dropping out after baseline will be in pattern 1,
patients dropping out after month 3 will be in
pattern 2 and so on, and patients with a valid
month 24 form will be in pattern P ¼ 6. Note that
within each pattern p 6¼ 1, patients may have
missing forms before dropout. Also, patterns are
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defined on the basis of valid forms; occasionally
even if the form is valid, the VAS score may have
not been filled in or may have been illegible. For a
patient in pattern p with observations yij; . . . ; yip
(some of which may be missing), observations yij
after dropout are imputed from the conditional
distribution of yij given yi1; . . . ; yip from a higher
pattern for which this distribution can be esti-
mated. Pattern-mixture models can be further di-
vided according to which pattern is used to impute
missing observations from. Pattern-mixture mod-
els are underidentified and hence identifying
restrictions need to be made in order to make the
model identifiable. Since we are assuming MAR
for intermediate missing observations, we only
need to impute for patterns p ¼ 1; . . . ; P  1. For a
patient in pattern p, we only need to impute
observations p þ 1; . . . ; P . We consider the fol-
lowing three methods (for more details refer to [9],
Section 20.5):
Complete cases missing values (CCMV): All
missing observations after dropout are imputed
from the conditional distribution of the pattern
corresponding to patients with complete data. In
our case this is the last pattern, pattern P .
Neighboring cases missing values (NCMV): A
missing observation yij for j > p of patient i is
imputed using the conditional distribution of
pattern j.
Available cases missing values (ACMV): A
missing observation yij for j > p of patient i is
imputed using the conditional distribution of a
randomly chosen pattern (j; . . . ; P ). The probabil-
ities pk, k ¼ j; . . . ; P of imputing from pattern k are
designed in such a way that dropout is missing at
random.
Imputation of missing data is repeated a number
of times; the completed data are analyzed for each
of the patterns separately using mixed models and
the estimates are combined afterwards. The vari-
ances of estimates within and between imputations
are combined (see for instance [9], Section 20.3 for
a more detailed description of this multiple
imputation method).
Differences between treatment groups for each
of the above methods were assessed by defining
contrasts and testing their significance using
Wald’s test.
All analyses in this subsection were done with
S-plus 2000 (Insightful Corporation).
Results
Assessment of missingness
A total of 1530 randomized Dutch patients were
approached for the TME quality of life substudy.
For the present analysis, we excluded 50 patients
that were ineligible, 37 patients that never had any
surgery, 52 that died in hospital, and 89 that did
not consent. Excluding those patients left 1302
patients for the present study. Thirty of those pa-
tients never actually had a valid quality of life
measurement, 906 completed quality of life fol-
lowup. Of those, 609 (67%) had filled in each form
on time, 143 (16%) only missed their pretreatment
form.
For the baseline measurement, a total of 216
forms were received too late. Of those, 76 (6%)
were received after start of radiotherapy, 93 (7%)
after surgery, and 47 (4%) did not have a date on
the form.
Table 1 summarizes baseline VAS scores, de-
pending on whether the corresponding quality of
life forms were dated before, at, or after day of
randomization, radiotherapy and surgery, respec-
tively. Baseline VAS scores did not differ accord-
ing to whether forms were dated before, at or after
day of randomization, neither for all patients, nor
for treatment groups separately. Baseline VAS
scores differed according to whether forms were
dated before, at, or after day of radiotherapy
(RTþTME group only, p ¼ 0:020) and day of
surgery (p < 0:001 for all patients; p ¼ 0:003 for
the RTþTME group, p ¼ 0:005 for the TME
group). A post-hoc comparison with Bonferroni
correction indicated significant differences of
baseline VAS scores between patients who filled in
their forms before and after day of radiotherapy
(p ¼ 0:016) and between patients who filled in
their forms before and after day of surgery
(p < 0:001). We did not find any significant dif-
ferences between treatment groups, for any of the
time-frames (before, at, or after day of randomi-
zation, before, at, or after day of surgery). Based
on these findings, pretreatment forms dated after
start of radiotherapy and at or after surgery were
considered missing; pretreatment forms dated at or
after day of randomization but before start of
radiotherapy and surgery were considered for
analysis, resulting in 991 valid baseline forms.
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Table 2 summarises how many forms were re-
ceived too late, at baseline and at each following
scheduled time point. Table 2 also shows the
compliance at every measurement. Mean compli-
ance was 84%; only at baseline compliance was
below 80% (71.1% in the RTþTME group,
81.1% in the TME group; p < 0:001), the reason
being that many forms were filled out after surgery
or after start of radiotherapy. From month 3 on,
compliance was consistently somewhat higher (1–
2%) in the RTþTME group; this difference was
nowhere significant, however.
Table 3 contains the results of the comparison
for patients with complete quality of life followup,
between the three categories described in section
Assessment of missingness. The differences in n-
values is explained by the fact that the subgroups
are defined with respect to missing forms, not
missing VAS scores, see also section Assessment of
missingness. For month 3 and month 24, the VAS
scores differ significantly between the three cate-
gories (p ¼ 0:034 both for month 3 and month
24). Post-hoc tests indicate that the categories with
complete data and baseline only missing do not
differ, and that the ‘other’ category is lower than
the baseline only missing group at month 3
(Bonferroni-corrected p ¼ 0:045) and from the
complete group at month 24 (Bonferroni-corrected
p ¼ 0:032). No statistically significant differences
were found in either of the treatment groups, nor
were there any statistically significant differences
between treatment groups.
Comparison of analysis strategies
Table 4 contains the results of the available cases
analysis and the mixed model approach. At base-
line and at 3months the estimated means are vir-
tually identical for the two strategies; from month
6 on, the linear mixed model gives slightly lower
means, the difference in means between the avail-
able cases and the mixed model analyses increases
with time. At 24months, the available cases anal-
ysis mean estimates are two points (2.5 standard
errors) higher than those of the mixed model. As
expected, the available cases analysis estimates are
biased upwards, because it is based on a sample of
healthier patients, the sick ones having dropped
out. The differences between the treatment groups









































































































































































































































































































































































































































































































































































































































































For the pattern-mixture model analysis, the
percentages of patients in patterns 1 through 6
were 2.5, 3.4, 5.7, 6.4, 10.2 and 71.8, respectively.
We calculated the means and 95% confidence
intervals of the VAS scores for each of the six
patterns. The result is shown graphically in Figure 1.
Table 2. Assessment of missing forms
Baseline Month 3 Month 6 Month 12 Month 18 Month 24 Total
Total alive at previous time 1302 1302 1293 1280 1230 1180
Dead in interval 0 9 13 50 50 50 172
No of forms possible 1302 1293 1280 1230 1180 1130 7415
Total missing 311 160 157 175 195 224 1222
Not received 95 88 119 138 164 190
No disease 87 78 94 104 120 140
LR 4 4 7 4
DR 2 9 14 20 26
LR + DR 1 4 8
R2 or M1 at surgery 8 8 12 13 13 12
Too late 169 34 5 12 6 14
After surgery 93
After RT 76
Date missing 47 38 33 25 25 20
Received on time 991 1133 1123 1055 985 906 6193
Compliance (%) 76.1 87.6 87.7 85.8 83.5 80.2 83.5
LR – local recurrence, DR – distant recurrence; R2 – residual tumor, M1 – metastasis, RT – radiotherapy. Note that 991 pre-forms
were filled in on time. Of these, 26 were filled in before the day of randomization, as originally required, 47 on the day of randomization
itself, and 918 after randomization.
Table 3. Comparison of VAS scores for patients with complete quality of life followup
Mean 95% CI p-Value
Baseline Complete (n = 605) 76.9 (75.6–78.2)
Baseline missing (n = 0) – –
Other (n = 105) 76.9 (73.8–79.9) 0.98
Months 3 Complete (n = 596) 76.1 (74.8–77.4)
Baseline missing (n = 141) 77.1 (74.5–79.7)
Other (n = 94) 71.8 (68.1–75.5) 0.034
Month 6 Complete (n = 602) 77.5 (76.3–78.7)
Baseline missing (n = 142) 78.4 (75.6–81.2)
Other (n = 115) 76.9 (74.4–79.3) 0.73
Month 12 Complete (n = 598) 78.8 (77.5–80.1)
Baseline missing (n = 141) 79.5 (76.6–82.3)
Other (n = 110) 75.8 (73.0–78.6) 0.15
Month 18 Complete (n = 599) 78.9 (77.6–80.1)
Baseline missing (n = 137) 77.2 (74.3–80.1)
Other (n = 98) 77.3 (73.3–81.2) 0.42
Month 24 Complete (n = 604) 77.9 (76.6–79.2)
Baseline missing (n = 140) 76.3 (73.1–79.5)
Other (n = 147) 73.7 (70.4–77.1) 0.034
Patients are divided into three categories: complete forms, baseline forms missing (forms are complete with the exception of baseline
forms), and other. p-Values are based on one-way analysis of variance.
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It clearly shows that mean VAS scores are
higher for the patients in pattern 6, strongly
indicating a violation of the MCAR assumption.
Each of the patterns shows a decrease at
3months compared to baseline and a decline to-
wards the time of dropout. A continuation of this
decline until at or after time of dropout (not
observed of course, but not unlikely either) would
be a violation of the MAR assumption (i.e.,
implying MNAR).
Table 5 contains the results of the pattern-
mixture model approach under three possible
Table 4. Estimated means (SE) of VAS scores for two approaches of dealing with missing values; available cases and a linear mixed
model
Available cases Linear mixed model
RT + TME TME p-Value RT + TME TME p-Value
Baseline 76.88 (0.74) 74.92 (0.78) 0.070 76.85 (0.79) 74.77 (0.74) 0.054
Month 3 73.29 (0.78) 74.41 (0.72) 0.29 73.28 (0.74) 74.48 (0.73) 0.25
Month 6 76.24 (0.69) 75.66 (0.75) 0.57 75.74 (0.74) 75.34 (0.73) 0.70
Month 12 76.16 (0.80) 77.27 (0.75) 0.32 75.60 (0.75) 76.68 (0.75) 0.31
Month 18 76.90 (0.80) 77.48 (0.80) 0.61 75.82 (0.77) 75.81 (0.77) 0.97
Month 24 77.11 (0.84) 76.96 (0.83) 0.90 75.82 (0.79) 75.03 (0.80) 0.49
p-Values refer to the hypothesis of equality of mean quality of life values for RT + TME and TME only groups.
Figure 1. VAS means and error bars (95% confidence intervals) for different patterns.
Table 5. Estimated means (SE) of VAS scores for three strategies of imputing missing values in pattern-mixture models
CCMV NCMV ACMV
RT + TME TME p-Value RT + TME TME p-Value RT + TME TME p-Value
Baseline 76.86 (0.75) 74.94 (0.70) 0.061 76.90 (0.75) 74.95 (0.70) 0.057 76.89 (0.76) 74.95 (0.71) 0.060
Month 3 73.09 (0.70) 74.70 (0.69) 0.099 73.18 (0.71) 74.49 (0.70) 0.18 73.12 (0.72) 74.65 (0.69) 0.12
Month 6 75.49 (0.70) 75.60 (0.68) 0.91 75.70 (0.82) 75.25 (0.72) 0.66 75.27 (0.71) 75.40 (0.69) 0.90
Month 12 75.17 (0.70) 76.94 (0.69) 0.067 74.73 (0.84) 75.85 (0.72) 0.27 74.74 (0.77) 76.49 (0.71) 0.077
Month 18 75.85 (0.69) 76.19 (0.68) 0.72 75.08 (0.75) 74.95 (0.72) 0.90 75.30 (0.75) 75.44 (0.71) 0.89
Month 24 76.10 (0.70) 75.53 (0.67) 0.55 75.93 (0.71) 75.02 (0.68) 0.34 75.73 (0.72) 75.28 (0.68) 0.64
p-Values refer to the hypothesis of equality of mean quality of life values for RT + TME and TME only groups.
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strategies of imputing missing values: CCMV,
NCMV, and ACMV.
The three imputation methods give very similar
results. No clear pattern emerges in the sense of
one method giving higher mean values than the
other. Each of the three imputation methods is
also very similar to the linear mixed model analysis
of Table 4.
Discussion
We have assessed missing values and dropout in
the TME quality of life substudy. With regard to
baseline forms, we found that, although strictly
speaking only forms dated before the day of ran-
domization should be included, there is little harm
in including also forms filled in at or even after day
of randomization. Apparently, knowing what
treatment a patient gets does not influence the
VAS score. Of 991 eligible pre-forms, only 26 were
filled in before the day of randomization, as orig-
inally required, 47 on the day of randomization
itself, and 918 after randomization, so adhering to
the protocol would leave only 26 or at most 73
patients with valid baseline forms. We have
therefore decided to admit 918 baseline forms da-
ted after randomization, but not after radiother-
apy or surgery. One would expect radiotherapy
and/or surgery to have a larger impact on quality
of life scores. This was also confirmed by our
findings, which clearly shows lower VAS scores at
or after day of radiotherapy/surgery as compared
to before day of radiotherapy/surgery.
We discussed a hierarchy of types of missing-
ness: missing completely at random (MCAR),
missing at random (MAR) and missing not at
random (MNAR). An error-bar plot of VAS
scores for each of six patterns separately (patterns
defined by time of dropout) clearly indicated that
the MCAR assumption was violated and even
suggested the possibility of violation of MAR.
Patients with complete quality of life followup had
higher VAS scores; early dropout was associated
with lower quality of life. The distinction between
MAR and MNAR is intrinsically more difficult; in
fact testing violation of MAR requires assump-
tions (to make the model identifiable) which are
themselves untestable. Differences between esti-
mates obtained from statistical models assuming
MAR and MNAR could indicate violation of
MAR, but could also be caused by an incorrect
choice of identifying restrictions. To assess the
influence of these identifying restrictions we fitted
three models with different identifying restrictions:
complete cases missing values (CCMV), neigh-
boring cases missing values (NCMV) and available
cases missing values (ACMV). This sensitivity
analysis revealed no important differences between
the estimates obtained from these models. More-
over, each of those methods gave very similar re-
sults to the linear mixed model approach, which is
valid under the MAR assumption. Note that this
does not necessarily mean that data are missing at
random. In fact, Figure 1 is somewhat suggestive
of violation of MAR, since one could well imagine
the decline in, e.g., pattern 2 to continue past
month 3. However, dropout rates were too low
(pattern 2, e.g., constituting only 3.4% of all pa-
tients) for the pattern-mixture models (represent-
ing only moderate deviations from MAR) to pick
up an effect of any violation of MAR on VAS
scores. Since pattern-mixture models are compu-
tationally considerably involved, for this quality of
life analysis the linear mixed model approach was
found to be an attractive method of analysis
yielding accurate estimates of mean VAS scores
and differences between treatment groups.
Even if different statistical models yield different
estimates of quality of life, when the main objec-
tive is to study differences in quality of life between
two or more treatments, differences in quality of
life estimates may not be a problem as long as
estimates of differences in quality of life remain
similar across different models. Differences in
quality of life estimates but not in quality of life
treatment differences may occur when dropout is
considerable (and probably related to disease
progression and quality of life) but comparable for
the different treatments. For this quality of life
substudy of the TME study there is a priori reason
to suspect that dropout due to local recurrence is
higher in the TME only arm. In fact, this expec-
tation was one of the incentives to undertake this
comparative analysis.
A number of other papers ([9], Section 20.6,
[12]) have shown substantial differences between
the quality of life estimates based on different
choices of statistical models. Those were studies
concerned with diseases in advanced stages like
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metastatic breast cancer and metastatic lung can-
cer, based on patient populations with high mor-
tality and high disease progression, resulting in
high percentage of missing values. The fact that we
did not find major differences in our data between
the results from models assuming MAR and
MNAR could be very well explained by the fact
that in our study morbidity and mortality were low
and the percentage of data missing was at most
moderate. A number of recent studies on quality
of life in patients with early-stage Hodgkin’s dis-
ease [13] and non-small-cell lung cancer [14] with
comparable or even higher degree of missingness
also reported similar results under MAR and
MNAR. Given this fact, it is all the more striking
that the estimates obtained from the available
cases analysis were so different. This is a clear
warning to interpret results based on available
cases analyses with considerable care.
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